thoracic surgery
Recently Published Documents





2022 ◽  
Vol 32 (1) ◽  
pp. 91-102
Luis A. Godoy ◽  
Elise Hill ◽  
David T. Cooke

2022 ◽  
Vol 32 (1) ◽  
pp. 67-74
Sakib M. Adnan ◽  
Michael Poulson ◽  
Virginia R. Litle ◽  
Cherie P. Erkmen

2022 ◽  
Vol 32 (1) ◽  
pp. 83-90
Kyle G. Mitchell ◽  
Ian C. Bostock ◽  
Mara B. Antonoff

2022 ◽  
Vol 17 (1) ◽  
Wei Li ◽  
Chunbo Zhai ◽  
Jianpeng Che ◽  
Weiqian Wang ◽  
Bingchun Liu

Abstract Background Immune checkpoint inhibitors were used for patients with advanced non-small cell lung cancer (NSCLC) more and more frequently and the effects were thrilling. Toripalimab as a new immune checkpoint inhibitor has been shown to be effective in patients with advanced NSCLC. However, data regarding the safety and feasibility of surgical resection after treatment with toripalimab for NSCLC remain scarce. Here, we present a case with locally advanced NSCLC that received video-assisted thoracic surgery (VATS) lobectomy after treatment with toripalimab in combination with chemotherapy. Case presentation A 62-year-old male patient with a history of coronary artery stenting operation for two times was found a 3.4 × 3.2 cm cavity mass in the upper lobe of the left lung and enlarged left hilar and mediastinal lymph nodes. Pathological results identified squamous cell carcinoma. The patient was diagnosed with a locally advanced NSCLC and received VATS left upper lobectomy and lymph node dissection after neoadjuvant chemotherapy plus toripalimab for 3 cycles. The postoperative pathological results showed complete tumor remission. Short-term follow-up results were excellent, and long-term results remain to be revealed. Conclusions Our preliminary results showed that the use of neoadjuvant toripalimab and chemotherapy for the locally advanced NSCLC before surgical resection is safe and feasible.

Sign in / Sign up

Export Citation Format

Share Document